Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20089 Combination Therapy in Advanced Solid Tumors
NCT06336707Phase 1Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mocertatug rezetecan in solid tumor (advanced stage) (4 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Maximum Tolerated Dose or Maximum Applicable Dose up to 21 days. Started Apr 2024; status: recruiting.
02
Drugs
mocertatug rezetecan
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06336707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06336707.